SCHEMBL24344996

SCHEMBL24344996

COc1nccc(OC2CC2)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
LRRK2 Q5S007 6/20 0.39
PDE4A P27815 3/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
HTR1A P08908 2/20 0.35
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
ALDH1A1 P00352 1/20 0.34
DRD1 P21728 1/20 0.33
KCNH2 Q12809 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
S1PR1 P21453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24344995 0.81 LRRK2 (0.35) HCRTR1HCRTR2LRRK2PDE4AHPGD
SCHEMBL29534763 0.81 LRRK2 (0.35) HCRTR1HCRTR2LRRK2PDE4AHPGD
SCHEMBL24344934 0.81 LRRK2 (0.35) HCRTR1HCRTR2LRRK2PDE4AHPGD
SCHEMBL4074890 0.79 ALDH1A1 (0.44) HPGDSMN1; SMN2ALDH1A1DRD1
SCHEMBL25344006 0.76 LRRK2 (0.43) LRRK2PDE4ACHRNB4CHRNA3KCNH2
SCHEMBL25347949 0.76 LRRK2 (0.43) LRRK2PDE4ACHRNB4CHRNA3PDE4B
SCHEMBL29534561 0.75 MEN1 (0.42) LRRK2SMN1; SMN2ALDH1A1
SCHEMBL24344461 0.75 MEN1 (0.42) LRRK2SMN1; SMN2ALDH1A1
SCHEMBL4076975 0.74 ATP4A (0.38) HPGDSMN1; SMN2ALDH1A1DRD1
SCHEMBL26670647 0.72 HCRTR1 (0.41) HCRTR1HCRTR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076975-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed